KKR

Business profile & competitive position

KKR & Co. Inc. sits in the Financial Services sector and, more specifically, the Asset Management industry. The firm operates as an alternative-asset manager: it raises capital from institutional limited partners and retail vehicles, deploys it across private equity, credit, real estate, infrastructure and related strategies, and earns revenue from management fees, performance fees and investment income. That structure means profitability depends on both the volume of fee-paying capital and the realized value of the deals KKR buys, improves and exits.

The current profitability figures suggest a scaled but capital-intensive franchise rather than a purely fee-driven, high-margin compounder. Net margin is 14.9% and return on equity is 10.3%. Those numbers imply KKR earns a real but moderate premium over its cost of equity, and that a meaningful share of capital is continuously reinvested into new funds and co-investments. In asset management, the closest thing to a durable moat is persistent fund performance and long-term limited-partner relationships. KKR’s margins and ROE indicate it has competitive strength, but not a moat so wide that results are insulated from deal-cycle volatility, credit spreads or exit-window timing.

Financial posture

KKR currently commands a $92.3 billion market capitalization and trades at a P/E ratio of 30.6. That multiple sits above the long-run market average and is consistent with investors paying up for long-dated fee streams and carried-interest optionality. The 14.9% net margin supports the premium, while the 10.3% ROE is more pedestrian: it signals KKR must keep raising and deploying capital efficiently to justify the valuation.

Risk is amplified by a beta of 1.79. That statistic implies KKR’s stock has historically moved roughly 1.8 times the broader market, making it effectively a leveraged play on financial conditions, credit spreads, exit activity and asset prices. No specific balance-sheet debt figure is supplied here, but the elevated beta alone confirms the equity behaves like a cyclical, capital-markets-sensitive name even though KKR itself is not a bank.

Macro & geopolitical exposure

As an Asset Management business focused on private markets, KKR is exposed to the macro channels that drive fundraising, deal financing and exits. Interest rates are the most direct transmission mechanism: higher rates raise the cost of leveraged buyouts, compress portfolio-company valuations, and can delay IPO and M&A exit windows. Credit spreads matter because cheap debt has historically expanded purchase-price multiples; when spreads widen, deal math becomes harder. Currency swings affect the reported value of international assets, including the recent Medicover India acquisition denominated in euros.

Regulation is a persistent factor, ranging from SEC private-fund rulemaking to antitrust scrutiny of large buyouts and cross-border investment reviews. Trade policy and geopolitical tension can also influence sector allocations, supply-chain decisions and foreign-investment approvals. Real estate and infrastructure holdings add further sensitivity to inflation, rates and government infrastructure policy. The 1.79 beta suggests the market already prices a high degree of responsiveness to these macro and geopolitical variables.

Recent developments

August 2026 has been unusually active for KKR deal headlines. On August 3, 2026, The Wall Street Journal reported that KKR agreed to buy Integer Holdings for $4.3 billion. Then on August 6, 2026, Reuters reported that Medicover would sell its India hospital business to KKR for €1.2 billion, while BusinessWire carried KKR’s own announcement that it would acquire leading multi-specialty healthcare provider Medicover India. Also on August 6, 2026, PR Newswire reported FS KKR Capital Corp.’s second-quarter 2026 results and its declared third-quarter 2026 distribution of $0.44 per share.

Healthcare dominates the visible deal flow. The Integer and Medicover India transactions together signal continued appetite for medical devices, hospital operations and related services. FS KKR Capital Corp. is a separate business-development-company affiliate, but the distribution announcement reinforces the ecosystem of fee- and dividend-paying vehicles tied to the KKR platform. None of these individual headlines alone moves the $92.3 billion market-cap needle, but the clustering shows KKR is actively deploying capital at a time when many private-equity peers have slowed.

Earnings behavior & post-earnings drift

KKR has delivered strong quantitative earnings performance. Over the last eight reported quarters, it beat the published consensus 7 of 8 times, an 88% beat rate, with an average earnings surprise of 6.6%. Yet post-earnings price drift has been essentially absent: the average five-day move following those reports is 0.17%, classified as flat.

The last four quarters illustrate how a beat does not guarantee a rally. On July 30, 2026, KKR reported $1.63 EPS against a $1.43 estimate, a 14% surprise, and the stock rose 0.45% the next session and 2.35% over the following five days. On May 5, 2026, a $1.39 print versus a $1.26 estimate, a 10.3% surprise, still produced a 1.19% one-day decline and a 2.48% five-day decline. The February 5, 2026 quarter was the lone miss in the set: $1.12 actual versus $1.14 estimate, a -1.8% surprise, yet the stock gained 4.06% the next day and 1.97% over five days. Finally, the November 7, 2025 report delivered $1.41 EPS against $1.30 estimate, an 8.5% beat, followed by a 1.0% next-day drop and a 1.15% five-day decline.

The pattern points to a stock where the official estimate and the market’s real expectation can diverge, and where positive news is frequently discounted ahead of the release. KKR is scheduled to report next on November 6, 2026, before the open, with a consensus EPS estimate of $1.58. At the August 9, 2026 snapshot, the price is $102.81, RSI is 55.3 and the 50-day EMA is $98.66, leaving the stock a few percent above its medium-term moving average heading into the fall reporting window.

For investors evaluating KKR, the intersection of strong earnings beats, a premium valuation and a high-beta macro profile makes the company a case study in private-market cyclicality rather than a simple value or growth call. To dig deeper, review the full institutional verdict on the ticker page, including analyst ratings, target ranges and consensus revisions, to see how the sell-side is interpreting the recent deal flow and the November 2026 reporting setup.